Britain and America have signed a major commercial pact that will guarantee no import taxes on UK medicine products being sold in the American market.
The Terms of the Pact
Under the terms of the agreement, the UK has pledged to raise spending on drugs through the NHS. This move guarantees that tariffs on these vital goods will be held at nothing for a timeframe of the next three years.
This agreement comes after previous threats to dramatically increase duties on patented drug imports, with potential rates discussed up to one hundred percent.
"This arrangement between the Britain reinforces the international landscape for new treatments and introduces long-overdue balance to American-British drug exports," a release declared.
Trade Significance
Medicines represent one of the UK's largest exports to the America, which is by far the primary market for large companies like GSK and AstraZeneca.
Statistics indicate that in the one-year period prior to the third quarter, the UK shipped pharmaceutical products valued at billions to the US. This figure made up 17.4% of total UK exports in that timeframe.
"This deal safeguards work, increases investment and paves the way for the UK to emerge as a international leader for medical research," the Business and Trade Secretary stated.
Detailed NHS Changes
The pact entails several key commitments from the British government:
- Price Threshold Increase: The UK will raise the cost ceiling at which it considers new treatments to be prohibitively costly by a quarter.
- Higher Drug Budget: There is a target to double total health service expenditure on drugs from 0.3% of the national economy to 0.6% over the coming ten years.
- Rebate Cap: The amount drug companies must return to the NHS to stay within budget will be capped at fifteen percent. Last year, refunds were more than twenty percent.
Broader Context
This agreement takes place against a long-running tension between the drug companies and the British authorities over drug pricing and regulatory access.
These tensions were exacerbated by claims that American patients were charged a premium for the same drugs than patients in the other developed nations.
Over the last 18 months, several large manufacturing plans in the UK have been delayed or scrapped, while multi-billion-dollar investments have been directed toward projects in the United States.
A senior figure publicly accepted that the NHS needed to spend more on medicines, noting that its expenditure on drugs had decreased as a percentage of its total funding over the previous ten-year period.
